OSR Holdings subsidiary Vaximm enters term sheet with BCM Europe for VXM01 license; $20M upfront, up to $815M milestones

OSR Holdings, Inc.

Non-binding term sheet with BCM Europe AG for exclusive global license of VXM01 oral cancer immunotherapy.
Potential $20M upfront payment plus up to $815M in clinical, regulatory, and commercial milestones.
Six-month exclusivity period for negotiations; due diligence and board approvals required.
BCM Europe is OSRH's largest shareholder; deal includes optional blockchain-based royalty mechanism (TAC tokens).
Vaximm retains IP ownership; definitive agreement would grant BCME exclusive global rights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.